Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital

Personalized Medicine

Volumn 5, Issue 6, 2008, Pages 579-587

  Ruanño, Gualberto ^a   Villagra, David ^a   Rahim, Umme Salma ^b   Windemuth, Andreas ^a   Kocherla, Mohan ^a   Bower, Bruce ^a   Szarek, Bonnie L ^b   Goethe, John W ^b  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Alleles; CYP2C19; CYP2C9; CYP2D6; Drug metabolism; Patient safety; Pharmacogenetics; Psychotropic drug safety

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; FLUOXETINE; LAMOTRIGINE; METHYLPHENIDATE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DEPRESSION; DNA FINGERPRINTING; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

EID: 57749177273     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.6.579     Document Type: Article

References (33)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
2. de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47, 75-85 (2006).
3. Mrazek DA: Clinical implementation of psychiatric pharmacogenomic testing. Pers. Med. 2, 93-95 (2005).
4. Mrazek DA: Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice. CNS. Spear. 11, 3-4 (2006).
5. Black JL, III, O'Kane DJ, Mrazek DA: The impact of CYP allelic variation on antidepressant metabolism: a review. Expert Opin. Drug Metab. Toxicol. 3, 21-31 (2007).
6. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
7. Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1356-1358 (2006).
8. Ruaño G, Blair CL, Bower B et al.: Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies. Conn. Med. 71, 197-200 (2007).
9. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics. J. 5, 6-13 (2005).
10. Wedlund PJ, de Leon J: Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin. Pharmacol. Ther. 75, 373-375 (2004).
11. LLerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28 (1993).
12. LLerena A, Berecz R, Dorado P, Gonzalez AP, Penas-LLedo EM, De La Ruhia A: CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics. J. 3, 300-302 (2003).
13. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
14. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
15. Dahl ML: Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470 (2002).
16. Gervasini G, Martinez C, Agundez JA, Garcia-Gamito FJ, Benitez J: Inhibition of cytochrome P450 2C9 activity in vitro by 5-bydroxytryptamine and adrenaline. Pharmacogenetics 11, 29-37 (2001).
17. de Leon J, Susce MT, Johnson M et al.: A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 92, 95-102 (2007).
18. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
19. Gurwitz JH, Field TS, Harrold LR et al.: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289, 1107-1116 (2003).
20. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
21. Ernst FR, Grizzle AJ: Drug-related morbidity and mortality: updating the cost-of-illness model. J. Am. Pharm. Assoc. (Wash.) 41, 192-199 (2001).
22. Johnson M, Markham-Abedi C, Susce MT, Murray-Carmichael E, McCollum S, de Leon J: A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr. 11, 757-760 (2006).
23. Ruaño G, Thompson PD, Windemuth A et al.: Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6, 865-872 (2005).
24. Ruaño G, Makowski G, Windemuth A et al.: High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: implications for personalized drug safety. Pers. Med. 3, 131-137 (2006).
25. Melis R, Lyon E, McMillin GA: Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays. Expert Rev. Mol. Diagn. 6, 811-820 (2006).
26. Gordon J, Merante F, Weiss S, Zastawny R: Pharmacogenetic P-450 screening using the Tag-It universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling The Practice of Personalized Medicine. Wong SH, Linder MW, Valdes R (Eds). AAC Press, Washington. DC, USA (2006).
27. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pbarmacogenetics 13, 173-181 (2003).
28. Facciola G, Hidestrand M, von Bahr C, Tybring G: Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur. J. Clin. Pharmacol. 56, 881-888 (2001).
29. Wilke RA, Moore JH, Burmester JK: Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 15, 415-421 (2005).
30. Cai WM, Nikoloff DM, Pan RM et al.: CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics. J. 6, 343-350 (2006).
31. Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ: CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 8, 721-730 (2007).
32. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet. Med. 9, 819-825 (2007).
33. Andersson T, Flockhart DA, Goldstein DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78, 559-581 (2005).